# Inmunotek S.L. clinical trials: 26 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 26 trials with Inmunotek S.L. as lead sponsor, 11 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Inmunotek S.L.: 26 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/inmunotek-s-l

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 26
- Recruiting or not yet: 11
- Read on: November 19, 2026

## Trials

The 25 newest of 26, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 29, 2026 | NCT07904195 | Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis\_MM09-SIT-069. | Inmunotek S.L. | Phase 3 | Recruiting | Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904195) |
| October 29, 2026 | NCT07904052 | Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063. | Inmunotek S.L. | Phase 3 | Recruiting | Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904052) |
| February 23, 2026 | NCT07427576 | Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte | Inmunotek S.L. | Observational | Completed | Mite Allergy, Dermatophagoides Farinae Allergy, Dermatophagoides Pteronyssinus Allergy, Rhinitis, Allergic, Asthma... | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07427576) |
| January 16, 2026 | NCT07348302 | Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df | Inmunotek S.L. | Phase 3 | Recruiting | Rhinitis, Rhinoconjunctivitis | 736 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07348302) |
| September 29, 2025 | NCT07195929 | Determination of Blomia Tropicalis Allergen Extract in Prick Test Units | Inmunotek S.L. | Not applicable | Not yet recruiting | Allergic Reactions, Allergic Skin Reaction | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07195929) |
| May 4, 2025 | NCT06957496 | Phleum Pratense and Dactylis Glomerata Allergen Extracts Standardization | Inmunotek S.L. | Not applicable | Completed | Allergy Pollen, Allergic Reaction, Allergic Skin Reaction | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06957496) |
| January 24, 2025 | NCT06790368 | Immunotherapy for the Treatment of Hymenoptera Venom Allergy in Real-life Conditions. | Inmunotek S.L. | Observational | Recruiting | Allergy, Insect Venom, Allergy Insect Stinging, Insect Sting Allergy | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06790368) |
| January 17, 2025 | NCT06782217 | Prospective Observational Study to Evaluate the Safety of Immunotherapy as a Treatment for Hymenoptera Venom Allergy | Inmunotek S.L. | Observational | Recruiting | Allergy, Insect Venom, Allergy Insect Stinging, Insect Sting Allergy | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06782217) |
| December 7, 2022 | NCT05641272 | Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract | Inmunotek S.L. | Phase 2/3 | Not yet recruiting | Allergic Rhinitis, Allergic Asthma, Allergic Rhinoconjunctivitis, Allergy to House Dust Mite | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05641272) |
| September 9, 2022 | NCT05533385 | Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation. | Inmunotek S.L. | Not applicable | Completed | Allergy Pollen, Allergic Reaction, Allergic Skin Reaction | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05533385) |
| September 8, 2022 | NCT05532566 | Quercus Ilex and Quercus Robur Allergen Extracts Standardisation | Inmunotek S.L. | Not applicable | Recruiting | Allergic Reaction, Allergic Skin Reaction, Allergy Pollen | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05532566) |
| June 2, 2022 | NCT05400811 | Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis | Inmunotek S.L. | Phase 3 | Unknown | House Dust Mite Allergy, Perennial Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05400811) |
| January 26, 2022 | NCT05208060 | Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells | Inmunotek S.L. | Phase 1/2 | Unknown | Immune Response | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05208060) |
| May 24, 2021 | NCT04898283 | Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. | Inmunotek S.L. | Phase 3 | Recruiting | Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04898283) |
| May 18, 2021 | NCT04891237 | Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen | Inmunotek S.L. | Phase 3 | Recruiting | Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04891237) |
| May 6, 2021 | NCT04874714 | Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis | Inmunotek S.L. | Phase 3 | Terminated | Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis, House Dust Mite Allergy, Pollen Allergy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04874714) |
| June 30, 2020 | NCT04452643 | Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel | Inmunotek S.L. | Phase 3 | Withdrawn | Covid19 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04452643) |
| June 17, 2020 | NCT04435990 | Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites | Inmunotek S.L. | Phase 3 | Recruiting | Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04435990) |
| April 27, 2020 | NCT04363814 | Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection | Inmunotek S.L. | Phase 3 | Unknown | COVID-19 | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04363814) |
| January 25, 2016 | NCT02661854 | Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy | Inmunotek S.L. | Phase 2 | Unknown | Rhinitis, Rhinoconjunctivitis | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02661854) |
| January 13, 2016 | NCT02654223 | Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy | Inmunotek S.L. | Phase 2 | Completed | Rhinitis, Rhinoconjunctivitis | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02654223) |
| September 7, 2015 | NCT02543827 | Evaluation of the Efficacy and Safety of MV140 | Inmunotek S.L. | Phase 3 | Completed | Urinary Tract Infection Bacterial | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02543827) |
| August 18, 2015 | NCT02527187 | Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa | Inmunotek S.L. | Phase 2 | Completed | Immune System Diseases | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02527187) |
| August 18, 2015 | NCT02527122 | Biological Stardadization of D. Pteronyssinus and D. Farinae Allergen Extracts | Inmunotek S.L. | Not applicable | Completed | Immune System Diseases | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02527122) |
| April 29, 2013 | NCT01842360 | Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD) | Inmunotek S.L. | Phase 2/3 | Completed | Chronic Obstructive Pulmonary Disease (COPD) | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01842360) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1/2 | 1 |
| Phase 2 | 3 |
| Phase 2/3 | 2 |
| Phase 3 | 12 |
| Not applicable | 5 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 9 |
| Recruiting | 9 |
| Unknown | 4 |
| Not yet recruiting | 2 |
| Withdrawn | 1 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hypersensitivity | 15 |
| Rhinitis, Allergic | 8 |
| Dust Mite Allergy | 5 |
| Rhinitis, Allergic, Seasonal | 4 |
| Asthma | 4 |
| Rhinitis | 4 |
| Rhinitis, Allergic, Perennial | 2 |
| COVID-19 | 2 |
| Immune System Diseases | 2 |
| Venom Hypersensitivity | 2 |
| Pulmonary Disease, Chronic Obstructive | 1 |
| Urinary Tract Infections | 1 |
| Bronchial Spasm | 1 |
| Bronchiolitis | 1 |
| Bronchitis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Financial services firms in the United States](https://specstream.ai/data/businesses/financial-services-firms/united-states)
- [Welding companies in the United States](https://specstream.ai/data/businesses/welding-companies/united-states)
- [Logging companies in the United States](https://specstream.ai/data/businesses/logging-companies/united-states)
- [Business office supplies and stationery companies in the United States](https://specstream.ai/data/businesses/business-office-supplies-and-stationery-companies/united-states)
- [Public utilities in the United States](https://specstream.ai/data/businesses/public-utilities/united-states)
- [Farm equipment repair companies in the United States](https://specstream.ai/data/businesses/farm-equipment-repair-companies/united-states)
